Telomir Pharmaceuticals Changes Accountants
Ticker: TELO · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1971532
Sentiment: neutral
Topics: auditor-change, financial-reporting
TL;DR
Telomir dumped its accountants, no new ones hired yet.
AI Summary
Telomir Pharmaceuticals, Inc. announced on December 16, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, Semple, Benner, Marotta & Co., P.L.L.C., effective December 16, 2024. The company has not yet appointed a new independent registered public accounting firm.
Why It Matters
A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial reporting issues or a change in company strategy.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- Semple, Benner, Marotta & Co., P.L.L.C. (company) — Dismissed Certifying Accountant
- December 16, 2024 (date) — Date of dismissal of accountant
FAQ
When was the change in certifying accountant effective?
The change in certifying accountant was effective on December 16, 2024.
Who was Telomir Pharmaceuticals' previous certifying accountant?
Telomir Pharmaceuticals' previous certifying accountant was Semple, Benner, Marotta & Co., P.L.L.C.
Has Telomir Pharmaceuticals appointed a new certifying accountant?
No, Telomir Pharmaceuticals has not yet appointed a new independent registered public accounting firm.
What is the principal executive office address for Telomir Pharmaceuticals?
The principal executive office address is 100 SE 2nd St, Suite 2000, #1009, Miami, Florida 33131.
What is the SEC file number for Telomir Pharmaceuticals?
The SEC file number for Telomir Pharmaceuticals is 001-41952.
Filing Stats: 898 words · 4 min read · ~3 pages · Grade level 15.5 · Accepted 2024-12-20 17:00:32
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex16-1.htm (EX-16.1) — 6KB
- ex16-1_001.jpg (GRAPHIC) — 17KB
- 0001493152-24-051090.txt ( ) — 250KB
- telo-20241216.xsd (EX-101.SCH) — 3KB
- telo-20241216_lab.xml (EX-101.LAB) — 33KB
- telo-20241216_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TELOMIR PHARMACUTICALS, INC. Dated: December 20, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer